Jenna Koliani-Pace, MD
Gastroenterology · Glastonbury, CTNPI 1316209141
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $56,797 with a category attached, or 88.0%. Pfizer accounts for 88.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $50,831 and has fallen 95.6% since, to $2,232 in 2025. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $183.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$50K
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$731
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$384
- Lilly USA, LLC$238
- plus $1K from 23 others
Across 3 payments — averaging $43.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$131
What the payments were for
- Consulting fees$190%
- Speaking & faculty fees$1400%
- Grants$50,00088%
- Food & beverage$6,54212%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $50,362 |
| AbbVie(2 entities) | 119 | $2,531 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $1,244 |
| Johnson & Johnson | 35 | $731 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $384 |
| Lilly USA, LLC | 10 | $238 |
| Ironwood Pharmaceuticals, Inc | 8 | $169 |
| Gilead | 8 | $140 |
| Madrigal Pharmaceuticals | 4 | $123 |
| Boston Scientific | 1 | $113 |
| Sanofi | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
| Exact Sciences | 3 | $59 |
| Bristol Myers Squibb | 2 | $54 |
| UCB, Inc. | 3 | $52 |
| Amgen | 2 | $44 |
| Braintree Laboratories, Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $41 |
| AMAG Pharmaceuticals, Inc. | 2 | $40 |
| Intercept Pharmaceuticals, Inc. | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| QOL Medical, LLC | 1 | $33 |
| Merck | 2 | $29 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Ardelyx, Inc. | 1 | $21 |
| Biocon Biologics Inc | 1 | $20 |
| Celltrion USA Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Entyvio$125
How this compares
$56,797 in reported general payments places this provider in the 90th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $265,060 |
| Skyrizi On-BodyRisankizumab-Rzaa | 12 | $223,633 |
| CreonLipase/Protease/Amylase | 14 | $33,254 |
| MotegrityPrucalopride Succinate | 18 | $10,747 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 53 | $8,719 |
| Mesalamine ErMesalamine | 25 | $2,786 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 46 | $2,614 |
| Colestipol Hcl | 20 | $1,877 |
| Famotidine | 78 | $1,639 |
| Omeprazole | 91 | $1,194 |
| Pantoprazole Sodium | 77 | $813 |
| Lansoprazole | 20 | $658 |
| Sucralfate | 14 | $306 |
| Esomeprazole Magnesium | 12 | $260 |
| Hydrocortisone | 13 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $731 | $265,06011 claims |
| AbbVieCreon | $2,531 | $33,25414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,244 | $10,74718 claims |
| Braintree Laboratories, Inc.Sutab | $42 | $8,71953 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Glastonbury
- Joseph CappaGlastonbury$200K
- Paul FeuerstadtHamden$1M
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
- Renuka UmashankerHamden$197K
- David HassHamden$173K
- Michael EinsteinHartford$139K
- Pramod MistryNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.